Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Liquid Biopsy for Minimal Residual Disease Detection in Head and Neck Squamous Cell Carcinoma (LIONESS): A personalized cell-free tumor DNA analysis for patients with HNSCC.

Baseline (pre-surgery) ctDNA detection was 94.28%. Recurrence occurred in 8/11 (72.7%) patients who were ctDNA-positive during follow-up vs 0/24 who were ctDNA-negative (P=7e-7). In all 8 clinical recurrences, ctDNA was detected first, with lead times of 56 to 265 days. Post-surgery ctDNA was detected at variant allele fractions as low as 0.0005%.

ASCO Annual Meeting 2022